StreetInsider.com News Articles

Form 4 Anixa Biosciences Inc For: Jul 15 Filed by: Titterton Lewis H jr

Thu, 16 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260716/26777416.html

Form 4 Anixa Biosciences Inc For: Jul 15 Filed by: Titterton Lewis H jr

Thu, 16 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260716/26777416.html

Form 4 Anixa Biosciences Inc For: Jul 10 Filed by: KUMAR AMIT

Mon, 13 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260713/26760607.html

Form 4 Anixa Biosciences Inc For: Jul 10 Filed by: KUMAR AMIT

Mon, 13 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260713/26760607.html

Anixa ovarian cancer CAR-T trial advances to fifth dose cohort

Mon, 06 Jul 2026 08:32:11 -0400

Anixa Biosciences (NASDAQ: ANIX) announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1 clinical trial evaluating an FSHR-targeted CAR-T therapy for recurrent ovarian cancer, conducted at Moffitt Cancer Center.

The patient received a dose of 1×10⁷ CAR-positive cells per kilogram following lymphodepletion, the highest dose level evaluated in the study to date. No dose-limiting toxicities have been observed across any cohort through the prior dose level of 3×10⁶/kg CAR-T cells.

According to the company's press release, five patients in the trial have surpassed one year of survival following treatment, with individual patients surviving approximately

Anixa ovarian cancer CAR-T trial advances to fifth dose cohort

Mon, 06 Jul 2026 08:32:11 -0400

According to the company's press release, five patients in the trial have surpassed one year of survival following treatment, with individual patients surviving approximately

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Mon, 06 Jul 2026 08:30:00 -0400

Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date

Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion

SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Mon, 06 Jul 2026 08:30:00 -0400

Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date

Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Mon, 06 Jul 2026 08:30:00 -0400

Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date

Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Mon, 06 Jul 2026 08:30:00 -0400

Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date

Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion

Anixa Biosciences receives South Korean patent for breast cancer vaccine

Mon, 29 Jun 2026 08:45:45 -0400

Anixa Biosciences (NASDAQ: ANIX) announced that South Korea's Ministry of Intellectual Property has issued Patent Number 10-2960889 covering the company's breast cancer vaccine technology, providing protection in that market through 2040.

The composition-of-matter patent is exclusively licensed from Cleveland Clinic and covers Anixa's approach to breast cancer prevention based on immunizing against human α-lactalbumin, a protein associated with lactation that is expressed in certain breast cancer types. No preventive breast cancer vaccine is currently approved anywhere in the world.

The Korean patent adds to Anixa's existing portfolio in the United States and other international markets. According to the company's press release, a

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Mon, 29 Jun 2026 08:45:00 -0400

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate

Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients

SAN JOSE, Calif., June 29, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Mon, 29 Jun 2026 08:45:00 -0400

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate

Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Mon, 29 Jun 2026 08:45:00 -0400

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate

Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Mon, 29 Jun 2026 08:45:00 -0400

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate

Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients

Anixa shares Phase 1 data on breast cancer vaccine and CAR-T therapy

Fri, 26 Jun 2026 09:10:21 -0400

Anixa Biosciences (NASDAQ: ANIX) presented data from two clinical-stage immunotherapy programs at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium, according to a company press release.

The breast cancer vaccine, developed in collaboration with Cleveland Clinic, completed a Phase 1 trial in which all major primary endpoints were met. The vaccine was reported to be safe and well tolerated at the maximum tolerated dose, and protocol-defined immune responses were generated in 74% of participants. The presentation, titled "Phase I Trial of an Alpha-Lactalbumin (aLA) Vaccine for Breast Cancer," was delivered by Dr. Emily Esakov Rhoades, FDA/IND Trial Program

Anixa shares Phase 1 data on breast cancer vaccine and CAR-T therapy

Fri, 26 Jun 2026 09:10:21 -0400

Anixa shares Phase 1 data on breast cancer vaccine and CAR-T therapy

Fri, 26 Jun 2026 09:10:21 -0400

Anixa shares Phase 1 data on breast cancer vaccine and CAR-T therapy

Fri, 26 Jun 2026 09:10:21 -0400

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontier

Fri, 26 Jun 2026 09:10:00 -0400

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants

Ovarian cancer CAR-T therapy, lira-cel, presentation highlights positive survival observations from ongoing Phase 1 clinical trial

Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions, including Cleveland Clinic and Moffitt Cancer Center